Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTITUSSIVE vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
FDA-approved: Symptomatic relief of nonproductive cough,Off-label: Cough associated with upper respiratory tract infections, chronic bronchitis, COPD
Management of mild to moderate pain,Reduction of fever
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Metabolism varies by agent: Dextromethorphan is metabolized via CYP2D6; codeine (opioid antitussive) is metabolized via CYP2D6 to morphine; benzonatate is metabolized by plasma esterases.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 35-45% bound to plasma albumin.
10-25% bound to albumin at therapeutic concentrations.
Vd approximately 3-5 L/kg, indicating extensive tissue distribution.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral: approximately 40-50% due to first-pass metabolism.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, avoid if possible.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Dextromethorphan: 2-6 years: 2.5-5 mg every 4-6 hours; 6-12 years: 5-10 mg every 4-6 hours; >12 years: adult dose. Codeine: not recommended for children due to safety concerns.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at lowest effective dose; monitor for sedation, constipation, and falls; avoid codeine if possible; dextromethorphan: 10 mg every 6-8 hours.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
N/A (No black box warning for general antitussives; specific agents like benzonatate have warnings for severe allergic reactions and accidental ingestion in children.)
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Do not exceed recommended dosage (risk of toxicity, especially with dextromethorphan abuse).,Caution in patients with respiratory depression, asthma, or chronic cough due to smoking or COPD.,Avoid in children <2 years (risk of serious adverse events).
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to the specific antitussive agent.,Concomitant use of MAOIs or within 14 days (risk of serotonin syndrome with dextromethorphan).,Respiratory depression (especially opioid-containing antitussives).
Hypersensitivity to acetaminophen or any component of the formulation
Grapefruit juice may increase absorption of dextromethorphan, potentially increasing side effects. Avoid alcohol as it enhances CNS depression. No specific food restrictions for codeine, but avoid high-tyramine foods if taking MAOIs concurrently.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal respiratory depression and withdrawal if used near term; possible association with congenital malformations in first trimester, but evidence inconclusive. Avoid use in first trimester and near term.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Dextromethorphan: Low levels in breast milk; M/P not established; generally compatible. Codeine: M/P ratio ~2.5; risk of CNS depression in infant; use caution or avoid. Monitor infant for sedation.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No specific pharmacokinetic changes require dose adjustment for dextromethorphan. Codeine metabolism may be altered due to pregnancy-induced changes in CYP2D6; individual dose titration recommended, but avoid use if possible.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Antitussives like dextromethorphan are effective for nonproductive cough but should not be used in patients with chronic productive cough due to potential suppression of necessary mucus clearance. Abuse potential exists with dextromethorphan at high doses; monitor for serotonin syndrome when combined with MAOIs or SSRIs. Codeine-containing antitussives require caution in CYP2D6 ultra-rapid metabolizers due to risk of morphine toxicity.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take only for dry, hacking cough; do not use for cough with phlegm unless directed by a doctor.,Do not exceed recommended dose; excessive use can lead to serious side effects including confusion, hallucinations, and rapid heart rate.,Avoid alcohol and sedatives as they may increase drowsiness and respiratory depression.,Seek medical attention if cough persists >1 week, or is accompanied by fever, rash, or headache.,Do not combine with other cough/cold products containing the same active ingredients.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTITUSSIVE vs INJECTAPAP, answered by our medical review team.
ANTITUSSIVE is a Antitussive that works by Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTITUSSIVE and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTITUSSIVE is: For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTITUSSIVE and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTITUSSIVE is classified as Category C. Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.